MedTrace Logo

Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)

NCT01874457 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2013-06-17

No results posted yet for this study

Summary

On a previous study conducted in Brazil. The MMR vaccine from 2 different producers had a mumps seroconversion much lower (71%) than the expected 95%, according to the package insert. This could indicate that a substantial proportion of children was not protected after MMR dose.

Conditions

Interventions

BIOLOGICAL

MMR (Mumps, Measles and Rubella)

MMR (Mumps, Measles and Rubella)

Sponsors & Collaborators

  • The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

    lead OTHER

Principal Investigators

  • Glória Regina da Silva e Sá, Doctorate · Immunobiological Technology Institute (Bio-Manguinhos)

Eligibility

Min Age
12 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-03-31
Completion
2009-08-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874457 on ClinicalTrials.gov